We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cellular Biomedicine Group Inc | NASDAQ:CBMG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 19.74 | 19.74 | 19.80 | 0 | 01:00:00 |
Delaware
|
001-36498
|
86-1032927
|
||
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
530 University Avenue, #17
Palo Alto, California
|
94301
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Cellular Biomedicine Group, Inc.
|
|||
Date: November 19, 2014
|
By:
|
/s/ Bizuo (Tony) Liu
|
|
Bizuo (Tony) Liu
|
|||
Chief Financial Officer |
● | The Company rang the Nasdaq Market Closing Bell as the first pure-play cell therapy company from China approved for listing on Nasdaq | |
● | Acquired Agreen Biotech Co. Ltd. China ("AG") and its founder's U.S. patent, adding to our technology platform CentrixTTM immune assessment and cancer immunotherapy technologies and products, which add emerging technical service revenue to the Company as well as 30 new talented personnel, enabling CBMG to expand beyond its Shanghai and Wuxi operations in China into northern regions of the country | |
● | Appointed Professor Zhong Chen Kou as Chief Scientist, Immunology to develop CentrixTTM immune assessment and cancer immunotherapy technologies and products |
● |
Completed patient enrollment for Phase IIb Clinical Trial for ReJoinTM regenerative medicine treatment of Knee Osteoarthritis (KOA)
|
|
● |
Released the positive six-month follow-up data analysis of its Phase I/IIa clinical trial for Rejoin™ regenerative medicine treatment of KOA
|
|
● |
Completed the 12-month follow-up of all patients in its Phase I/IIa clinical trial for Rejoin™ regenerative medicine treatment of KOA
|
|
● | Launched clinical research study for cartilage defect (CD) regenerative medicine stem cell therapy, which also serves as a supporting study of ReJoinTM for KOA | |
● | Strengthened the Company's IP portfolio with the addition of one new US patent, one China patent granted and the filing of two new international patents |
● |
The Company expects to present twelve month follow-up data analysis from its Phase I/IIa clinical trial for Rejoin™ regenerative medicine treatment of KOA on December 5, 2014 at the World Stem Cell Summit in San Antonio, Texas
|
|
● |
The Company expects to announce interim data from the Phase IIb trial for Rejoin™ regenerative medicine treatment of KOA in Q1 2015
|
|
● |
Company executives will participate in the J.P. Morgan Annual Healthcare Conference in San Francisco in January 2015
|
|
● |
In December 2014, the Company will file on a Form 8K historical and pro-forma financials relating to the acquisition of Agreen (“AG”), reporting a pro-forma revenue of over $1.2 million for the nine months ended September 30, 2014
|
1 Year Cellular Biomedicine Chart |
1 Month Cellular Biomedicine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions